Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 8.5% Higher – Here’s Why

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) were up 8.5% during trading on Friday . The company traded as high as $48.60 and last traded at $48.25. Approximately 891,774 shares were traded during trading, an increase of 25% from the average daily volume of 714,320 shares. The stock had previously closed at $44.49.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Oppenheimer reissued an “outperform” rating and set a $63.00 target price (up from $61.00) on shares of Tarsus Pharmaceuticals in a report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $51.60.

Tarsus Pharmaceuticals Price Performance

The firm has a market capitalization of $1.80 billion, a P/E ratio of -10.56 and a beta of 1.00. The company has a fifty day moving average of $33.97 and a 200 day moving average of $31.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.03 and a quick ratio of 6.99.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative net margin of 180.00% and a negative return on equity of 63.99%. The company had revenue of $40.81 million for the quarter, compared to analyst estimates of $31.30 million. During the same period in the prior year, the firm posted ($1.17) EPS. Sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.71 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Quest Partners LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at about $61,000. Canada Pension Plan Investment Board acquired a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter worth approximately $114,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after acquiring an additional 1,530 shares in the last quarter. Dark Forest Capital Management LP acquired a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $202,000. Finally, Bleakley Financial Group LLC bought a new position in Tarsus Pharmaceuticals during the first quarter worth $223,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.